Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering products and services, Synthego is at the forefront of innovation in engineered biology. 

Apprentice helps life science manufacturers get treatments to patients faster by providing one platform to turn molecules into medicine. Our Tempo Manufacturing Cloud lets you scale up and out with unprecedented speed and accuracy. From preclinical benchtop to large-scale commercial manufacturing, Tempo keeps your global teams connected, empowered, and in sync.

With $140M in funding, a 12x growth rate, and 512% net customer retention, Apprentice is a trusted partner to modernize your operations and change the way drugs are made in your facility. Learn how leading companies like Catalent, Synthego, and Bristol Myers Squibb are using Tempo to scale from drug discovery to patient delivery faster at www.apprentice.io.

Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 tools and services to support discoveries in fields such as regenerative medicine, immunotherapy, and disease research. Whether you’re culturing and editing hematopoietic stem and progenitor cells, differentiating pluripotent stem cells, or activating and expanding immune cells, we have the specialized cell isolation products, high-performance cell culture media, and accessory tools for your research. By increasing the accessibility of innovative techniques like gene editing and organoid cultures, we’re helping scientists accelerate the pace of discovery—so they can get therapies to patients faster. Researchers working towards clinical trials can also obtain guidance and customized support through our Services for Cell Therapy Program on qualifying our products for use as raw/ancillary materials. To learn more, visit www.STEMCELL.com.

Biopact CT has developed MGMR™, a unique non-biologic next generation transfection technology. This heavily patented and versatile intracellular delivery vehicle uses discrete hollow, nanoscale tubules approximately 1/10,000th the width of a human hair.  The high aspect-ratio, nanoscale profile of MGMR™ allows it to readily penetrate cells without compromising membrane integrity or inducing cytotoxicity. Its high surface-to-volume ratio and tunable surface chemistry allow it to transport both small and large-molecular cargos into the cytoplasm, including oligonucleotides, peptides, proteins and genetic materials, vector and genetic materials.

CTI Clinical Trial and Consulting Services is a privately held, full-service contract research organization, delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site, as well as complete global laboratory services. Now in its third decade, CTI is one of the 20 largest CROs in the world, with associates in more than 60 countries across six continents. CTI is headquartered in the Greater Cincinnati area, with operations across North America, Europe, Latin America, MEA and Asia-Pacific. For more information, visit www.ctifacts.com 

Inspiring advances in bioprocessing, Repligen is a technology leader in filtration, chromatography, systems, process analytics and Protein A ligand development for bioprocessing and gene therapy. Propelled by a culture of innovation and collaboration, and with a focus on cost and process efficiencies, our people and our technologies help address critical steps in the production of therapeutics, vaccines and diagnostics worldwide. Named one of the fastest-growing biotech companies in the USA, Repligen is headquartered in Boston, MA with major manufacturing sites in Massachusetts, California, New Jersey, Sweden, and Germany.

TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies.

For over 20 years, we have been working with our customers to create some of the most ground-breaking advances in cell and gene therapy tools and equipment.

Our team brings together expertise in biology, physics and engineering to enable bespoke solutions.

We support companies to reduce cost of goods and address variability and safety challenges, while scaling up new innovations. We combine our extensive experience of bioprocessing and cell handling, with our understanding of developing highly reliable medical devices – an approach we call Cell Therapy as a Medical Device (CTMD).

By using disruptive technologies and automation, TTP is advancing research, development, and manufacturing processes to make living medicines a reality for patients everywhere.

For more information, please contact cellandgene@ttp.com

Heidrick & Struggles is the premier provider of senior-level executive search, culture shaping, and leadership consulting services. We serve more than 70% of the Fortune 1000, with clients in virtually every industry and sector around the globe.

Advising leaders and organizations that are impacting global health and improving patients’ lives.

Global connectivity and the rapid pace of innovation have sharpened healthcare’s mission to provide value by improving the lives of human beings everywhere. Unprecedented health challenges, regulatory shifts, and a growing need to reevaluate delivery models have created a complex environment that requires leaders with a unique balance of passion and purpose.